Magali Haas

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia
    Magali Haas
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey, USA
    J Child Adolesc Psychopharmacol 19:611-21. 2009
  2. ncbi Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents
    Magali Haas
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey 08530, USA
    J Child Adolesc Psychopharmacol 18:337-45. 2008

Detail Information

Publications2

  1. ncbi A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia
    Magali Haas
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey, USA
    J Child Adolesc Psychopharmacol 19:611-21. 2009
    ..The aim of this study was to evaluate the efficacy and safety of two dose ranges of risperidone in adolescents with schizophrenia...
  2. ncbi Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents
    Magali Haas
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey 08530, USA
    J Child Adolesc Psychopharmacol 18:337-45. 2008
    ..The aim of this study was to determine the long-term safety of risperidone as maintenance therapy in children and adolescents with disruptive behavior disorders (DBDs) and normal intelligence...